[1]Ahn,SoonKil;Choi,NamSong;Jeong,ByeongSeon;Kim,KyeKwang;Journ,DuckJin;Kim,JoonKyum;Lee,SangJoon;Kim,JungWoo;Hong,ChungIl;Jew,Sang-sup[JournalofHeterocyclicChemistry,2000,vol.37,#5,p.1141-1144]
[1]Ahn,SoonKil;Choi,NamSong;Jeong,ByeongSeon;Kim,KyeKwang;Journ,DuckJin;Kim,JoonKyum;Lee,SangJoon;Kim,JungWoo;Hong,ChungIl;Jew,Sang-sup[JournalofHeterocyclicChemistry,2000,vol.37,#5,p.1141-1144]
213819-48-8
[1]CurrentPatentAssignee:SICHUANKELUNPHARMACEUTICALCOMPANYLIMITED-US2020/347075,2020,A1Locationinpatent:Paragraph0296-0299
213819-48-8
[1]CurrentPatentAssignee:SICHUANKELUNPHARMACEUTICALCOMPANYLIMITED-US2020/347075,2020,A1Locationinpatent:Paragraph0294-0295
[1]-CN116253741,2023,ALocationinpatent:Paragraph0089-0092
Title: Durable response after just one cycle of belotecan-based chemotherapy in a patient with relapsed primary peritoneal serous carcinoma.
Journal: The journal of obstetrics and gynaecology research 20140101
Title: Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120401
Title: Antitumor activity of CKD-602, a camptothecin derivative, in a mouse glioma model.
Journal: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20120201
Title: Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer.
Journal: Cancer chemotherapy and pharmacology 20120101
Title: Allometric scaling of pegylated liposomal anticancer drugs.
Journal: Journal of pharmacokinetics and pharmacodynamics 20111001
Title: Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors.
Journal: Journal of liposome research 20110601
Title: Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer.
Journal: Cancer 20110515
Title: Phase II study of belotecan (CKD 602) as a single agent in patients with recurrent or progressive carcinoma of uterine cervix.
Journal: Japanese journal of clinical oncology 20110501
Title: A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands) 20110401
Title: Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models.
Journal: Journal of liposome research 20110301
Title: Toxicity study of a new camptothecin anti-cancer agent CKD-602 in dogs: 4-week continuous intravenous dose by infusion pump and 4-week repeated intravenous dose.
Journal: Regulatory toxicology and pharmacology : RTP 20101101
Title: Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial.
Journal: Lung cancer (Amsterdam, Netherlands) 20101001
Title: A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands) 20100601
Title: Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer.
Journal: American journal of clinical oncology 20100601
Title: The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer.
Journal: Journal of chemotherapy (Florence, Italy) 20100601
Title: Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience.
Journal: The journal of obstetrics and gynaecology research 20100201
Title: Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer.
Journal: Cancer 20100101
Title: Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.
Journal: Clinical pharmacology and therapeutics 20091101
Title: Decreased urinary secretion of belotecan in folic acid-induced acute renal failure rats due to down-regulation of Oat1 and Bcrp.
Journal: Xenobiotica; the fate of foreign compounds in biological systems 20091001
Title: Phase I/IIa study of combination chemotherapy with CKD-602 and cisplatin in patients with recurrent epithelial ovarian cancer.
Journal: Annals of the New York Academy of Sciences 20090801
Title: CKD-602, a camptothecin derivative, inhibits proliferation and induces apoptosis in glioma cell lines.
Journal: Oncology reports 20090601
Title: Apoptotic effect of CKD-602 (Camtobell) on oral squamous cell carcinoma cell lines.
Journal: Oral oncology 20090301
Title: Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090215
Title: Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells.
Journal: Pharmaceutical research 20081101
Title: Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer.
Journal: Gynecologic oncology 20080601
Title: Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20080101
Title: Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20071201
Title: Effect of probenecid on the biliary excretion of belotecan.
Journal: Archives of pharmacal research 20071101
Title: A phase I and pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20071015
Title: Reproductive toxicity evaluation of a new camptothecin anticancer agent, CKD-602, in pregnant/lactating female rats and their offspring.
Journal: Cancer chemotherapy and pharmacology 20070201
Title: STEALTH liposomal CKD-602, a topoisomerase I inhibitor, improves the therapeutic index in human tumor xenograft models.
Journal: Anticancer research 20070101
Title: Evaluation of the toxic potentials of a new camptothecin anticancer agent CKD-602 on fertility and early embryonic development in rats.
Journal: Regulatory toxicology and pharmacology : RTP 20060801
Title: 4-Week repeated intravenous dose toxicity study of a new camptothecin anticancer agent CKD-602 in dogs.
Journal: Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20050501
Title: Effects of CKD-602, a new camptothecin anticancer agent, on pregnant does and embryo-fetal development in rabbits.
Journal: Drug and chemical toxicology 20050101
Title: Embryotoxic effects of CKD-602, a new camptothecin anticancer agent, in rats.
Journal: Reproductive toxicology (Elmsford, N.Y.) 20050101
Title: Subacute toxicity evaluation of a new camptothecin anticancer agent CKD-602 administered by intravenous injection to rats.
Journal: Regulatory toxicology and pharmacology : RTP 20041201
Title: CKD-602. Chong Kun Dang.
Journal: Current opinion in investigational drugs (London, England : 2000) 20031201
Title: Simple and sensitive determination of the new antitumor drug CKD-602 in human plasma by liquid chromatography.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030125
Title: Safety pharmacology of CKD-602, a novel anticancer agent.
Journal: Arzneimittel-Forschung 20030101
Title: In vitro pharmacodynamics of CKD-602 in HT-29 cells.
Journal: Archives of pharmacal research 20021001
Title: Preformulation studies of a novel camptothecin anticancer agent, CKD-602: physicochemical characterization and hydrolytic equilibrium kinetics.
Journal: International journal of pharmaceutics 20020604
Title: Kim YK, et al. Anticancer effects of CKD-602 (Camtobell?) via G2/M phase arrest in oral squamous cell carcinoma cell lines. Oncol Lett. 2015 Jan;9(1):136-142.
Title: Kim YY, et al. CKD-602, a camptothecin derivative, inhibits proliferation and induces apoptosis in glioma cell lines. Oncol Rep. 2009 Jun;21(6):1413-9.
Title: Kim CY, et al. Antitumor activity of CKD-602, a camptothecin derivative, in a mouse glioma model. J Clin Neurosci. 2012 Feb;19(2):301-5.
